Nigora Kadyrkhodjayeva
Goal: The purpose of the study was to review the efficacy, safety and tolerability of botulinum toxin A (BTX-A) as a prophylactic treatment in adults with chronic daily headache (CDH).
Material and methods: The study involved 100 patients with CDH comparing between two groups of patients. Group I, 54 patients (31 women and 23 men) treated by BTX-A, and group II, 46 patients (27 women and 21 men) treated with the classical method, with an average age of 35 ± 9 years.
Results: After 3 months headache severity in group I: 2 (3,7%) patients had no changes, 7 (12,9%) patients with less than 50 percent reduction in pain, 23 (42,6%) reported 70 to 95 percent pain relief, and 22 (40,8%) had complete relief. Group II: 12 (26,1%) patients had no changes, 16 (34,8%) patients with less than 50 percent reduction in pain, 10 (21,7%) reported 70 to 95 percent pain relief, and 8 (17,4%) had complete relief. The mean change from baseline frequency of headaches ranged from 3 ± 1 headaches per 30�?�day period in group I and 7±2 headaches in group II. This enhancement in catalytic performance was, however, more significant in the case of rod-shaped ceria.
Conclusion: In this study, BTX-A injections have been shown to be safe, well �?�tolerated, not any treatment-related serious adverse events reported. BTX-A injections recommended optimizing clinical outcomes for patients with CDH without using other prophylactic medications.